Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback